Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $91.71

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $92.79.

Several research firms recently weighed in on RARE. Piper Sandler dropped their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Monday, March 17th. Canaccord Genuity Group upped their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. HC Wainwright restated a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. JPMorgan Chase & Co. upped their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Wedbush reissued a “neutral” rating and set a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th.

Ultragenyx Pharmaceutical Trading Down 2.8 %

RARE stock opened at $37.82 on Tuesday. Ultragenyx Pharmaceutical has a one year low of $36.71 and a one year high of $60.37. The firm has a 50-day moving average of $41.64 and a two-hundred day moving average of $46.84. The firm has a market capitalization of $3.50 billion, a PE ratio of -5.97 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analysts’ expectations of $163.23 million. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 73,434 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $3,091,571.40. Following the sale, the chief executive officer now owns 641,731 shares of the company’s stock, valued at $27,016,875.10. The trade was a 10.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now directly owns 50,265 shares in the company, valued at $2,116,156.50. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 136,370 shares of company stock valued at $5,751,499. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently made changes to their positions in the company. California State Teachers Retirement System grew its stake in shares of Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock valued at $3,284,000 after purchasing an additional 268 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $5,505,000. Mackenzie Financial Corp lifted its position in Ultragenyx Pharmaceutical by 275.6% in the 4th quarter. Mackenzie Financial Corp now owns 16,115 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 11,825 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $82,000. Finally, Frazier Life Sciences Management L.P. boosted its holdings in Ultragenyx Pharmaceutical by 3.9% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 658,715 shares of the biopharmaceutical company’s stock worth $27,712,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.